Triple-negative breast cancer (TNBC) represents one of oncology's most demanding therapeutic challenges, characterized by its aggressive clinical behavior, hormone receptor deficiency (ER/PR), HER2 absence, and historically constrained treatment landscape. The Triple Negative Breast Cancer Treatment Market has undergone radical transformation throughout the preceding decade, driven by...